Questcor Pharma To Initiate Pilot Commercialization Effort For H.P. Acthar Gel

(RTTNews) - Questcor Pharmaceuticals Inc. (QCOR) announced that it plans to initiate a pilot commercialization effort for H.P. Acthar Gel (repository corticotropin injection) for the treatment of respiratory manifestations of symptomatic sarcoidosis, a potentially serious, difficult-to-treat disorder already included on the FDA-approved package insert for Acthar. The pilot effort will focus on pulmonologists, who are the respiratory specialists treating this rare autoimmune disorder.

The company anticipates hiring and training a small, pilot sales force of five to ten sales representatives during the current quarter, with introductory sales calls expected to begin in the fourth quarter of this year.

The company noted that it is also evaluating several potential clinical studies that have been recently proposed by key opinion leaders in the sarcoidosis field.